355 related articles for article (PubMed ID: 19720365)
1. Randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of live oral cholera vaccine 638 in Cuban adults.
Valera R; García HM; Jidy MD; Mirabal M; Armesto MI; Fando R; García L; Fernández R; Año G; Cedré B; Ramírez M; Bravo L; Serrano T; Palma S; González D; Miralles F; Medina V; Nuñez F; Plasencia Y; Martínez JC; Mandarioti A; Lugones J; Rodríguez BL; Moreno A; González D; Baro M; Solis RL; Sierra G; Barbera R; Domínguez F; Gutiérrez C; Kouri G; Campa C; Menéndez J
Vaccine; 2009 Nov; 27(47):6564-9. PubMed ID: 19720365
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
[TBL] [Abstract][Full Text] [Related]
3. Randomized placebo controlled human volunteer trial of a live oral cholera vaccine VA1.3 for safety and immune response.
Mahalanabis D; Ramamurthy T; Nair GB; Ghosh A; Shaikh S; Sen B; Thungapathra M; Ghosh RK; Pazhani GP; Nandy RK; Jana S; Bhattacharya SK
Vaccine; 2009 Jul; 27(35):4850-6. PubMed ID: 19523608
[TBL] [Abstract][Full Text] [Related]
4. [Tolerance and immunogenicity of an oral dose of CVD 103-HgR, a live attenuated Vibrio cholerae 01 strain: a double-blind study of Chilean adults].
Lagos R; Avendaño A; Horwitz I; Prado V; Ferreccio C; Sotomayor V; Losonsky G; Wasserman SS; Cryz S; Kaper JB
Rev Med Chil; 1993 Aug; 121(8):857-63. PubMed ID: 8296092
[TBL] [Abstract][Full Text] [Related]
5. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R
Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509
[TBL] [Abstract][Full Text] [Related]
6. Peru-15 (Choleragarde(®)), a live attenuated oral cholera vaccine, is safe and immunogenic in human immunodeficiency virus (HIV)-seropositive adults in Thailand.
Ratanasuwan W; Kim YH; Sah BK; Suwanagool S; Kim DR; Anekthananon A; Lopez AL; Techasathit W; Grahek SL; Clemens JD; Wierzba TF
Vaccine; 2015 Sep; 33(38):4820-6. PubMed ID: 26241948
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial.
Launay O; Sadorge C; Jolly N; Poirier B; Béchet S; van der Vliet D; Seffer V; Fenner N; Dowling K; Giemza R; Johnson J; Ndiaye A; Vray M; Sansonetti P; Morand P; Poyart C; Lewis D; Gougeon ML
Vaccine; 2009 Feb; 27(8):1184-91. PubMed ID: 19135496
[TBL] [Abstract][Full Text] [Related]
8. Development of Peru-15 (CholeraGarde), a live-attenuated oral cholera vaccine: 1991-2009.
Chowdhury MI; Sheikh A; Qadri F
Expert Rev Vaccines; 2009 Dec; 8(12):1643-52. PubMed ID: 19943759
[TBL] [Abstract][Full Text] [Related]
9. Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants.
Qadri F; Chowdhury MI; Faruque SM; Salam MA; Ahmed T; Begum YA; Saha A; Al Tarique A; Seidlein LV; Park E; Killeen KP; Mekalanos JJ; Clemens JD; Sack DA;
Vaccine; 2007 Jan; 25(2):231-8. PubMed ID: 16996172
[TBL] [Abstract][Full Text] [Related]
10. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali.
Perry RT; Plowe CV; Koumaré B; Bougoudogo F; Kotloff KL; Losonsky GA; Wasserman SS; Levine MM
Bull World Health Organ; 1998; 76(1):63-71. PubMed ID: 9615498
[TBL] [Abstract][Full Text] [Related]
11. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam.
Trach DD; Cam PD; Ke NT; Rao MR; Dinh D; Hang PV; Hung NV; Canh DG; Thiem VD; Naficy A; Ivanoff B; Svennerholm AM; Holmgren J; Clemens JD
Bull World Health Organ; 2002; 80(1):2-8. PubMed ID: 11884967
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age.
Saha A; Chowdhury MI; Khanam F; Bhuiyan MS; Chowdhury F; Khan AI; Khan IA; Clemens J; Ali M; Cravioto A; Qadri F
Vaccine; 2011 Oct; 29(46):8285-92. PubMed ID: 21907255
[TBL] [Abstract][Full Text] [Related]
13. Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial.
Kanungo S; Paisley A; Lopez AL; Bhattacharya M; Manna B; Kim DR; Han SH; Attridge S; Carbis R; Rao R; Holmgren J; Clemens JD; Sur D
Vaccine; 2009 Nov; 27(49):6887-93. PubMed ID: 19761838
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45.
McCarty JM; Lock MD; Hunt KM; Simon JK; Gurwith M
Vaccine; 2018 Feb; 36(6):833-840. PubMed ID: 29317118
[TBL] [Abstract][Full Text] [Related]
15. Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial Comparing the Reactogenicity and Immunogenicity of a Single Standard Dose to Those of a High Dose of CVD 103-HgR Live Attenuated Oral Cholera Vaccine, with Shanchol Inactivated Oral Vaccine as an Open-Label Immunologic Comparator.
Sow SO; Tapia MD; Chen WH; Haidara FC; Kotloff KL; Pasetti MF; Blackwelder WC; Traoré A; Tamboura B; Doumbia M; Diallo F; Coulibaly F; Onwuchekwa U; Kodio M; Tennant SM; Reymann M; Lam DF; Gurwith M; Lock M; Yonker T; Smith J; Simon JK; Levine MM
Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29021299
[TBL] [Abstract][Full Text] [Related]
16. [Community trial for safety and immunogenicity of oral-administered lyophilized rBS-WC cholera vaccine].
Chen Q; Yu S; Wang Y
Zhonghua Yu Fang Yi Xue Za Zhi; 1996 Nov; 30(6):330-3. PubMed ID: 9388905
[TBL] [Abstract][Full Text] [Related]
17. Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh.
Qadri F; Chowdhury MI; Faruque SM; Salam MA; Ahmed T; Begum YA; Saha A; Alam MS; Zaman K; Seidlein LV; Park E; Killeen KP; Mekalanos JJ; Clemens JD; Sack DA;
J Infect Dis; 2005 Aug; 192(4):573-9. PubMed ID: 16028125
[TBL] [Abstract][Full Text] [Related]
18. Palatability, reactogenicity and immunogenicity of engineered live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers.
Lagos R; San Martin O; Wasserman SS; Prado V; Losonsky GA; Bustamante C; Levine MM
Pediatr Infect Dis J; 1999 Jul; 18(7):624-30. PubMed ID: 10440439
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of escalating dosages of a single oral administration of peru-15 pCTB, a candidate live, attenuated vaccine against enterotoxigenic Escherichia coli and Vibrio cholerae.
Chen WH; Garza J; Choquette M; Hawkins J; Hoeper A; Bernstein DI; Cohen MB
Clin Vaccine Immunol; 2015 Jan; 22(1):129-35. PubMed ID: 25410205
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children.
Suharyono ; Simanjuntak C; Witham N; Punjabi N; Heppner DG; Losonsky G; Totosudirjo H; Rifai AR; Clemens J; Lim YL
Lancet; 1992 Sep; 340(8821):689-94. PubMed ID: 1355798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]